Zeitschriftenartikel zum Thema „Hypercholesteremia“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Hypercholesteremia" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Visavadiya, Nishant P., und A. V. R. L. Narasimhacharya. „AsparagusRoot Regulates Cholesterol Metabolism and Improves Antioxidant Status in Hypercholesteremic Rats“. Evidence-Based Complementary and Alternative Medicine 6, Nr. 2 (2009): 219–26. http://dx.doi.org/10.1093/ecam/nem091.
Der volle Inhalt der QuelleKamalova, Aelita A. „Diet Therapy in Children with Hypercholesteremia“. Current Pediatrics 19, Nr. 4 (19.09.2020): 309–15. http://dx.doi.org/10.15690/vsp.v19i4.2140.
Der volle Inhalt der QuelleDietrich, Hans H. „Apolipoprotein E in Hypercholesteremia and Beyond“. Stroke 38, Nr. 7 (Juli 2007): 2036. http://dx.doi.org/10.1161/strokeaha.107.489856.
Der volle Inhalt der QuelleLEWIS, S. „P514 Hypercholesteremia induces baroreceptro reflex dysfunction“. European Heart Journal 24, Nr. 5 (März 2003): 81. http://dx.doi.org/10.1016/s0195-668x(03)93952-2.
Der volle Inhalt der QuelleNAKAI, TSUGUHIKO. „Familial hypercholesteremia complicated by nephrotic syndrome.“ Nihon Naika Gakkai Zasshi 79, Nr. 8 (1990): 1079–80. http://dx.doi.org/10.2169/naika.79.1079.
Der volle Inhalt der QuelleHURLEY, D. „Hypercholesteremia induces enhanced circulating inflammatory activity“. American Journal of Hypertension 17, Nr. 5 (Mai 2004): S242. http://dx.doi.org/10.1016/j.amjhyper.2004.03.648.
Der volle Inhalt der QuelleLi, Nan F., Hong M. Wang, Jin Yang, Ling Zhou, Xiao G. Yao und Jing Hong. „Serum uric acid is associated with metabolic risk factors for cardiovascular disease in the Uygur population“. Applied Physiology, Nutrition, and Metabolism 34, Nr. 6 (Dezember 2009): 1032–39. http://dx.doi.org/10.1139/h09-101.
Der volle Inhalt der QuelleNichols, E. H., und M. R. Jaff. „Hypercholesteremia, Hypertension, and Antiplatelet Therapy in PAD“. MD Conference Express 13, Nr. 19 (01.12.2013): 31. http://dx.doi.org/10.1177/155989771319015.
Der volle Inhalt der QuelleKumawat, Vinod Bihari, Surendra Kumar Sharma, Uttam Kumar Sharma und Sudhir Sharma. „Effect of trikatu compound in hypercholesteremia- a clinical study“. Environment Conservation Journal 16, Nr. 1&2 (12.06.2015): 57–61. http://dx.doi.org/10.36953/ecj.2015.161209.
Der volle Inhalt der QuelleTokura, T. „Changes in Bruch's Membrane in Experimental Hypercholesteremia in Rats“. Japanese Journal of Ophthalmology 43, Nr. 4 (08.07.1999): 337–38. http://dx.doi.org/10.1016/s0021-5155(99)00055-6.
Der volle Inhalt der QuelleBARTON, M. „Hypercholesteremia induces cardiac concentric remodeling in the guinea pig“. American Journal of Hypertension 17, Nr. 5 (Mai 2004): S165—S166. http://dx.doi.org/10.1016/j.amjhyper.2004.03.434.
Der volle Inhalt der QuelleElbadawi, Ayman, Islam Y. Elgendy, Mohamed Omer, Mohamed Abdelazeem, Vijay Nambi, Chayakrit Krittanawong, Ravi S. Hira, Jacqueline Tamis-Holland, Christie Ballantyne und Hani Jneid. „Outcomes of Acute Myocardial Infarction in Patients with Familial Hypercholesteremia“. American Journal of Medicine 134, Nr. 8 (August 2021): 992–1001. http://dx.doi.org/10.1016/j.amjmed.2021.03.013.
Der volle Inhalt der QuelleYu, Lianlong, Qianrang Zhu, Yuqian Li, Pengkun Song und Jian Zhang. „Dietary Branched-Chain Amino Acids (BCAAs) and Risk of Dyslipidemia in a Chinese Population“. Nutrients 14, Nr. 9 (27.04.2022): 1824. http://dx.doi.org/10.3390/nu14091824.
Der volle Inhalt der QuelleNagaraj, Lavanya, und Naveen Kumar Madalageri. „A comparative study of metabolic side effects of risperidone and olanzapine in the treatment of schizophrenia“. International Journal of Basic & Clinical Pharmacology 8, Nr. 11 (22.10.2019): 2561. http://dx.doi.org/10.18203/2319-2003.ijbcp20194803.
Der volle Inhalt der QuelleKoo, Hui Chin, Lay Kim Tan, Geok Pei Lim, Chee Cheong Kee und Mohd Azahadi Omar. „Obesity and Its Association with Undiagnosed Diabetes Mellitus, High Blood Pressure and Hypercholesterolemia in the Malaysian Adult Population: A National Cross-Sectional Study Using NHMS Data“. International Journal of Environmental Research and Public Health 20, Nr. 4 (09.02.2023): 3058. http://dx.doi.org/10.3390/ijerph20043058.
Der volle Inhalt der QuelleDidia, S. Claudia. „PCSK9-Inhibitors: A Review of a Novel Approach in Hypercholesteremia Management“. Medical Science Review 1 (2014): 1–6. http://dx.doi.org/10.12659/msrev.890836.
Der volle Inhalt der QuelleVerma, Isha, Antonio Fernandez und Paul Thompson. „FAMILIAL HYPERCHOLESTEREMIA: WHEN STATINS, EZETIMIBE & PCSK9 INHIBITORS ARE NOT ENOUGH“. Journal of the American College of Cardiology 71, Nr. 11 (März 2018): A2439. http://dx.doi.org/10.1016/s0735-1097(18)32980-2.
Der volle Inhalt der QuelleVerma, Isha, Paul D. Thompson und Antonio B. Fernandez. „Familial Hypercholesteremia: When Statins, Ezetimibe & PCSK9 Inhibitors Are Not Enough“. Journal of Clinical Lipidology 12, Nr. 2 (März 2018): 545. http://dx.doi.org/10.1016/j.jacl.2018.03.043.
Der volle Inhalt der QuelleValentine, V. G., L. Seoane, D. M. Fuchs, S. G. LaPlace, G. A. Lombard und D. E. Taylor. „Potential benefits of treating hypercholesteremia and hypertension in lung allograft recipients“. Journal of Heart and Lung Transplantation 24, Nr. 2 (Februar 2005): S170. http://dx.doi.org/10.1016/j.healun.2004.12.105.
Der volle Inhalt der QuelleMUNDAY, J. „Hypercholesteremia-induced changes in left ventricular geometry in the guinea pig“. American Journal of Hypertension 17, Nr. 5 (Mai 2004): S168. http://dx.doi.org/10.1016/j.amjhyper.2004.03.441.
Der volle Inhalt der QuelleFan, Jing, Caicui Ding, Weiyan Gong, Fan Yuan, Yanning Ma, Ganyu Feng, Chao Song und Ailing Liu. „The Relationship between Leisure-Time Sedentary Behaviors and Metabolic Risks in Middle-Aged Chinese Women“. International Journal of Environmental Research and Public Health 17, Nr. 19 (30.09.2020): 7171. http://dx.doi.org/10.3390/ijerph17197171.
Der volle Inhalt der QuelleZhang, Haoqiang, Rong Huang, Sai Tian, Ke An, Wenwen Zhu, Jijing Shi, Wuyou Cao und Shaohua Wang. „The CC Genotype of Insulin-Induced Gene 2 rs7566605 Is a Protective Factor of Hypercholesteremia Susceptible to Mild Cognitive Impairment, Especially to the Executive Function of Patients with Type 2 Diabetes Mellitus“. BioMed Research International 2020 (10.06.2020): 1–7. http://dx.doi.org/10.1155/2020/4935831.
Der volle Inhalt der QuelleJha, Niharika, und Vanya Narayan. „Multiple giant tuberous xanthomas with type IIa hypercholesteremia in a young male“. Indian Journal of Dermatopathology and Diagnostic Dermatology 7, Nr. 1 (2020): 38. http://dx.doi.org/10.4103/ijdpdd.ijdpdd_40_20.
Der volle Inhalt der QuelleMiyayama, Takeshi, Shin-ichiro Miura, Tomo Komaki, Takashi Kuwano, Joji Morii, Hiroaki Nishikawa und Keijiro Saku. „Acute Myocardial Infarction in a 26-Year-Old Patient With Familial Hypercholesteremia“. Journal of Clinical Medicine Research 8, Nr. 7 (2016): 562–65. http://dx.doi.org/10.14740/jocmr2596w.
Der volle Inhalt der QuelleYakimenko, O., und Ie Maznichenko. „COMPLEX HYPOLIPIDEMIC THERAPY OF PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS AND FAMILIAL HYPERCHOLESTEREMIA“. Bulletin of Problems Biology and Medicine 1, Nr. 2 (2019): 207. http://dx.doi.org/10.29254/2077-4214-2019-1-2-149-207-211.
Der volle Inhalt der QuelleHyvärinen, Lea. „FLUORESCENCE CINEANGIOGRAPHIC AND HISTOLOGICAL STUDIES ON THE RABBIT EYE DURING EXPERIMENTAL HYPERCHOLESTEREMIA“. Acta Ophthalmologica 46, Nr. 1 (27.05.2009): 57–70. http://dx.doi.org/10.1111/j.1755-3768.1968.tb02495.x.
Der volle Inhalt der QuelleHarper, Claudia, Radhika Seimon, Brendon Yee, Amanda Sainsbury und Elizabeth Cayanan. „Translating Evidence into Practice: A Case Study of Extended Use of a Very Low Energy Diet for Treatment of Co-Morbid Obesity and Chronic Disease“. Recent Progress in Nutrition 2, Nr. 2 (21.02.2022): 1. http://dx.doi.org/10.21926/rpn.2202015.
Der volle Inhalt der QuelleBarrios, Vivencio, und Carlos Escobar. „Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk“. Expert Review of Clinical Pharmacology 14, Nr. 7 (24.05.2021): 793–806. http://dx.doi.org/10.1080/17512433.2021.1925539.
Der volle Inhalt der QuelleGodal, H. C., J. C. Lund und E. Sivertssen. „LIPIDS AND LIPOPROTEINS IN SERUM IN CASES OF FAMILIAL ESSENTIAL HYPERCHOLESTEREMIA AND XANTHOMATOSIS.“ Acta Medica Scandinavica 156, S319 (24.04.2009): 125–34. http://dx.doi.org/10.1111/j.0954-6820.1956.tb06306.x.
Der volle Inhalt der QuelleLi, Zhi-Zhao, Qiong Huang, Xiao-li Yang, Jieqiong Zeng, QI-Hui Wang, Hai-Ming Tang, Zhen-qiu Yu, Yu-Qing Song und Yang Liu. „Cholesterol Metabolic Markers for Differential Evaluation of Patients with Hyperlipidemia and Familial Hypercholesterolemia“. Disease Markers 2022 (21.04.2022): 1–9. http://dx.doi.org/10.1155/2022/2008556.
Der volle Inhalt der QuelleRANA, MOHAMMAD MOHSIN, BADAR BASHIR, MUHAMMAD SAEED AKHTAR und Abaid Ur-Rehman. „TYPE 2 DIABETICS“. Professional Medical Journal 14, Nr. 02 (06.09.2007): 337–43. http://dx.doi.org/10.29309/tpmj/2007.14.02.4900.
Der volle Inhalt der QuelleYuefeng, Yu, Lin Zhiqi, Chen Yi, Zhu Keyu, Wan Heng, Wang Yuying, Wang Ningjian et al. „Testosterone Deficiency Promotes Hypercholesteremia and Attenuates Cholesterol Liver Uptake via AR/PCSK9/LDLR Pathways“. International Journal of Endocrinology 2022 (13.05.2022): 1–10. http://dx.doi.org/10.1155/2022/7989751.
Der volle Inhalt der QuelleDrew-Nord, Dana C., OiSaeng Hong, Erika S. Froelicher, Phyllis Berryman und Eileen Lukes. „Cardiovascular Risk Factors among Career Firefighters“. AAOHN Journal 57, Nr. 10 (Oktober 2009): 415–24. http://dx.doi.org/10.1177/216507990905701004.
Der volle Inhalt der QuelleBardia, A., und G. Garg. „Mipomersen For Treatment Of Hypercholesteremia: Evidence Review And Meta Analytic Evaluation Of Randomized Controlled Trials“. Value in Health 18, Nr. 3 (Mai 2015): A132. http://dx.doi.org/10.1016/j.jval.2015.03.771.
Der volle Inhalt der QuelleNaik, Aleš Belič Adviti. „Analysis of the Cholesterol Biosynthesis Feedback Control and its Consequences for the Hypercholesteremia Treatment Strategies“. IFAC Proceedings Volumes 45, Nr. 2 (2012): 624–28. http://dx.doi.org/10.3182/20120215-3-at-3016.00111.
Der volle Inhalt der QuelleHuige, M. C., J. J. R. M. Bonnier, H. J. Rila, L. J. Jansen, K. te VElde, A. J. te Rijdt, P. de Weerd und P. A. Leijten. „Efficacy and safety of pravastatin in Dutch patients with hypercholesteremia and additional coronary risk factors“. Atherosclerosis 115 (Juni 1995): S128. http://dx.doi.org/10.1016/0021-9150(95)96739-f.
Der volle Inhalt der QuelleCheung, Brian, Jay Hwang, Ania Stolarczyk, Elliot Mahlof und Robert Block. „Case Study of Hypertriglyceridemia from COVID-19 Pfizer-BioNTech Vaccination in a Patient with Familial Hypercholesteremia“. Journal of Clinical Lipidology 16, Nr. 1 (Januar 2022): e13-e14. http://dx.doi.org/10.1016/j.jacl.2021.09.019.
Der volle Inhalt der QuelleKirkorowicz, JM, P. Sapukotana, PV De Silva, M. Noda, JS De Oliveira und T. Østbye. „Work-Related Stress and Substance Use as Risk Factors for Chronic Disease Among Three-Wheel Drivers in Galle, Sri Lanka: A Qualitative Study“. International Journal of Occupational Safety and Health 3, Nr. 2 (10.02.2014): 21–24. http://dx.doi.org/10.3126/ijosh.v3i2.7662.
Der volle Inhalt der QuelleEzratty, Ellen J., Claire Bertaux, Eugene E. Marcantonio und Gregg G. Gundersen. „Clathrin mediates integrin endocytosis for focal adhesion disassembly in migrating cells“. Journal of Cell Biology 187, Nr. 5 (30.11.2009): 733–47. http://dx.doi.org/10.1083/jcb.200904054.
Der volle Inhalt der QuelleCHISAKA, TAKESHI, HISASHI MATSUDA, YASUSHI KUBOMURA, MICHIHIKO MOCHIZUKI, JOHJI YAMAHARA und HAJIME FUJIMURA. „The effect of crude drugs on experimental hypercholesteremia: Mode of action of (-)-epigallocatechin gallate in tea leaves.“ CHEMICAL & PHARMACEUTICAL BULLETIN 36, Nr. 1 (1988): 227–33. http://dx.doi.org/10.1248/cpb.36.227.
Der volle Inhalt der QuelleWeng, Pei-Hsuan, Jen-Hau Chen, Ta-Fu Chen, Yu Sun, Li-Li Wen, Ping-Keung Yip, Yi-Min Chu und Yen-Ching Chen. „P3-253: Interactions between ApoE ε4 status and hypercholesteremia on response to acetylcholinesterase inhibitor in Alzheimer's disease“. Alzheimer's & Dementia 11, Nr. 7S_Part_16 (Juli 2015): P728. http://dx.doi.org/10.1016/j.jalz.2015.06.1626.
Der volle Inhalt der QuelleMIYAMURA, Mitsuhiko, Hironori MORIYAMA, Shuuzo MURATA, Junko YOKOTA, Saburo YOSHIOKA, Daisuke TAKUMA, Atsuhide HAMADA und Yutaka NISHIOKA. „Inhibitory Effects of “Goishi-tea” as a Post-Fermented-tea on Dietary-Induced Hypercholesteremia and Atherosclerosis in Rabbits“. YAKUGAKU ZASSHI 128, Nr. 7 (01.07.2008): 1037–44. http://dx.doi.org/10.1248/yakushi.128.1037.
Der volle Inhalt der QuelleAhualli, L., A. Stewart-Harris, G. Bastianelli, D. Radlovachki, A. Bartolomé, P. L. Trigo, N. Cejas et al. „Combined Cardiohepatic Transplantation Due to Severe Heterozygous Familiar Hypercholesteremia Type II: First Case in Argentina—A Case Report“. Transplantation Proceedings 39, Nr. 7 (September 2007): 2449–53. http://dx.doi.org/10.1016/j.transproceed.2007.07.068.
Der volle Inhalt der QuelleMatlock, John P., und J. E. Nixon. „Impaired clearance, elimination, and metabolism of plasma cholesterol esters associated with hypercholesteremia in mice fed cyclopropenoid fatty acids“. Toxicology and Applied Pharmacology 84, Nr. 1 (Juni 1986): 3–11. http://dx.doi.org/10.1016/0041-008x(86)90411-4.
Der volle Inhalt der QuelleKamal, Shymaa, Ragaa A. Hamouda, Hoda Mahrous, Mohammed Labib Salem, Hanafy A. Hamza und Ekbal Abd Elhafez. „In vitro Treatment with Intact Cells or Cell Lysates of Lactobacillus and Spirulina Induced Lowering Effects on Induced Hypercholesteremia“. International Journal of Pharmacology 11, Nr. 6 (01.08.2015): 638–43. http://dx.doi.org/10.3923/ijp.2015.638.643.
Der volle Inhalt der QuelleKim, Beob-Jin, Yeon-Kye Kim, Won-Hwan Park, Jeong-Heon Ko, Young-Choon Lee und Cheorl-Ho Kim. „A water-extract of the Korean traditional formulation Geiji–Bokryung–Hwan reduces atherosclerosis and hypercholesteremia in cholesterol-fed rabbits“. International Immunopharmacology 3, Nr. 5 (Mai 2003): 723–34. http://dx.doi.org/10.1016/s1567-5769(03)00073-0.
Der volle Inhalt der QuelleGopinathanpillai, Kalavarasariel, Eluri Kalpana, Balasubramaniam Dineshkumar, Elumalai Monogaran, Govindharajalu Geetha und Ramasamy Venkatanarayanan. „Tetrahydrocurcumin: Beneficial Effects on HMG-CoA Reductase enzyme and Lipoprotein Lipase Enzymes in High-fat diet-induced Hypercholesteremia Rabbits“. Pharmacognosy Communications 2, Nr. 2 (19.04.2012): 50–60. http://dx.doi.org/10.5530/pc.2012.2.8.
Der volle Inhalt der QuelleLi, Yun-Xi, Chao-Qun Lin, Da-Yu Shi, Shu-Ying Zeng und Wen-Sheng Li. „Upregulated expression of human alpha-defensins 1, 2 and 3 in hypercholesteremia and its relationship with serum lipid levels“. Human Immunology 75, Nr. 11 (November 2014): 1104–9. http://dx.doi.org/10.1016/j.humimm.2014.09.014.
Der volle Inhalt der QuelleWeintraub, Spencer, Jessica A. Schillow, Bani Azari und Benjamin Hirsh. „IMPLEMENTATION TIMELINE OF NOVEL LIPID LOWERING THERAPIES IN A REFRACTORY COMPOUND HETEROZYGOUS FAMILIAL HYPERCHOLESTEREMIA PATIENT WITH SEVERE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE“. Journal of the American College of Cardiology 79, Nr. 9 (März 2022): 3186. http://dx.doi.org/10.1016/s0735-1097(22)04177-8.
Der volle Inhalt der QuelleRani, Pratibha, Kamaldeep Singh, Anania Arjuna und Savita Devi. „GENETIC DISORDER ALZHEIMER“. Asian Journal of Pharmaceutical and Clinical Research 10, Nr. 12 (01.12.2017): 36. http://dx.doi.org/10.22159/ajpcr.2017.v10i12.18684.
Der volle Inhalt der Quelle